Dimerix Limited · ASX:DXB
Dimerix — Euroz Hartley Healthcare Forum 2024
27 slides from Dimerix's conference presentation, Feb 6, 2024
Slide 1: Dimerix presents at Euroz Hartley Healthcare Forum
Immediate Release DIMERIX PRESENTS AT EUROZ HARTLEY HEALTHCARE FORUM MELBOURNE, Australia, 06 February 2024: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presentin
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complic
Slide 3: Developing new therapies to treat inflammatory causes of kidney and respiratory disease
@w Dimerix nly CdDeveloping new therapies to treat inflammatory causes of re For personal (ASX:DXB) idney and respiratory disease with unmet clinical needs February 2024 Euroz Hartley Annual Conference ACTIONS FSGS CLINICAL STUDY Authorised for lodgement by the Board of the Company
Slide 4: Forward looking statements
? Forward looking Onal use only : his presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown ris! Gra important factors that may cause the actual results, performance or achievements of Dimerix to be materially differen
Slide 5: Lead Drug Candidate – DMX-200 in FSGS
Lead Drug Candidate – DMX-200 in focal segmental glomerulosclerosis (FSGS) For personal use only Market Opportunity Intellectual Property Commercialisation Outlook
Slide 6: Product development and commercialisation
Product development and commercialisation For personal use only • Complete Phase 3 clinical trial in FSGS (including clinical, non- 1 clinical manufacturing, IP, quality and regulatory) • Attract additional partners to: ➢Realise inherent value in existing assets ➢Provide early revenue and risk manag
Slide 7: Corporate overview
Corporate overview SHARE PRICE For personal use only .ASX Ticker Symbol ASX:DXB Chart generated on 1/V2024 at 4:57 pm ■dxb 1020 Cash Balance (Dec23) NA$14.8 million � 0.10 February March April May June Juty August September October November December January 2023 2024 Market Capitalisation NA$95 mill
Slide 8: For personal use only
Pre-clinical Phase 1 Phase 2 Phase 3 For personal use only FSGS Diabetic kidney disease Chronic obstructive pulmonary disease Multiple (undisclosed)
Slide 9: For personal use only
For personal use only • • • • • • • •
Slide 10: Orphan drug case study - Neuren
Orphan drug case study - Neuren (NEU.ASX) + Neuren are focussed on orphan disease treatment with a pipeline of rare neurodevelopmental disorders + Lead program/drug, DAYBUE™ (trofinetide) has orphan designation and received significant valuation uplifts during and after its Phase 3 program = $220m m
Slide 11: For personal use only
• • • For personal use only ▪ ▪ ▪ ▪ ▪ ▪
Slide 12: Global partnering availability
Global partnering availability or personal use only + Licensing deal marks the first of potentially several agreements globally 4 + Partnering discussion progressing in other territories @ Dimerix = 10
Slide 13: FSGS forecast market size
FSGS forecast market size Estimated diagnosed patients $US p.a (2022)!3 (e2032)'4 U S 3 b p.a! Estimated potential market size in FSGS 7MM ~$225 million $2 billion > Assuming US$9,900k/month as example pricing in the US (same pricing as sparsentan in IgAN)? ~$990 million > Current market specificall
Slide 14: Key elements of ADVANZ partnership
Key elements of ADVA\NZ partnership PHARMA Dimerix to receive up to “AU$230* million in upfront and milestone payments, plus royalties © €6,5 million in upfront payment (AU$10.8 million) ~ received in November 2023 © up to€132.5 million (“AU$218 million’) in potential development and sales milestone
Slide 15: Competitive landscape in FSGS
Competitive landscape in FSGS = Cc Phase 1 Phase 2 Company © DMX-200 @% avToyrRa Valenza Bio Soure @ Dimerix
Slide 16: Phase 3 clinical trial actions
PHASE 3 CLINICAL TRIAL ACTIGNS FSGS CLINICAL STUDY For personal use only @ Dimerix
Slide 17: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease For personal use only ATIR — blocked by angiotensin receptor blocker (ARB) a 1 Hyperfiltration of and hypertension within blood ves cinta inflam glomeruli infiltration Less filtering cells cause further hyperfiltration and ary cell of the CCR2 —CC
Slide 18: DMX-200 – working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (ATIR blocker): G protein-coupled receptor (GPCR) New Chemical Entity status, 2 x 120mg capsule daily with orphan exclusivity (7 For personal use only @ Dimerix years
Slide 19: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoi Clinically meaningful outcomes for patients For personal use only EFFICACY * 86% of patients demonstrated reduced proteinuria on DMX-200. versus placebo * 29% of patients nonstrated >40% duction in proteinuria * MCP-1 levels reduced by 39% when on DM
Slide 20: ACTION3 Phase 3 clinical trial
O ACTIGN3 Phase 3 clinical trial FSGS CLINICAL STUDY randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB prococd Part 1: 72 patients @ 35 weeks ' H proce eee eee en een e eno - == ~~ - Pat 2: 144 patients @ 35 weeks 1 w
Slide 21: For personal use only
For personal use only • • • • • • • • •
Slide 22: ACTION3 Part 1 analysis
¥ O » ACTING Part 1 analysis set FSGS CLINICAL STUDY >" Announcement of Part 1 analysis of Phase 3 trial expected on, or agin. 15 March 2024* * * Asuccessful outcome of the first analysis would represent a clinically and statistical meaningful improvement in proteinuria vs placebo and the trial is c
Slide 23: Lead Drug Candidate – DMX-200 in FSGS
Lead Drug Candidate – DMX-200 in focal segmental glomerulosclerosis (FSGS) For personal use only Licensed territories Market Opportunity Available for licensing Intellectual Property Commercialisation Outlook
Slide 24: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement le of. SCAN ME Dimeri
Slide 25: For personal use only
For personal use only
Slide 26: Advancing the broader pipeline
Advancing the broader pipeline Additional longer term pipeline opportunities diversify risk and potential sources of revenue DMX-700 for Chronic DMX-200 for Diabetic Undisclosed Opportunities Obstructive Pulmonary Kidney Disease Disease (COPD) Preclinical studies show that DMX-700 Phase 2 demonstrat
Slide 27: For personal use only
For personal use only Mark Diamond Nina Webster Hugh Alsop Sonia Poli Clinton Snow BSc, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Antisense, Faulding (Pfizer) Acrux,